The market for ivermectin is characterized by its use in both human and veterinary medicine, though its efficacy and regulatory status for treating COVID-19 remain subjects of scientific and public debate.
What is Ivermectin Used For?
Ivermectin is an antiparasitic drug primarily used to treat a variety of conditions caused by internal and external parasites in humans and animals. In humans, it is approved by the U.S. Food and Drug Administration (FDA) for treating river blindness (onchocerciasis) and strongyloidiasis [1]. It is also used to treat scabies and head lice [1]. For veterinary purposes, ivermectin is widely used to control internal and external parasites in livestock such as cattle, sheep, and pigs, and in companion animals [2].
Ivermectin's Role in COVID-19 Treatment
During the COVID-19 pandemic, ivermectin gained attention as a potential treatment. However, major health organizations, including the FDA and the World Health Organization (WHO), have stated that there is insufficient evidence to support its use for preventing or treating COVID-19 [1][3]. Numerous clinical trials have investigated ivermectin for COVID-19, but the results have been largely inconclusive or have not demonstrated a significant benefit [4]. Regulatory bodies in many countries have not approved ivermectin for this indication.
How is Ivermectin Marketed and Sold?
Ivermectin is available in various formulations, including oral tablets and topical creams. It is prescribed by healthcare professionals for approved indications. For veterinary use, it is available in different dosage forms, such as injectables, pour-ons, and feed additives, often sold through agricultural suppliers and veterinarians [2]. The market for ivermectin includes both branded and generic versions.
Who Makes Ivermectin?
Several pharmaceutical companies manufacture and distribute ivermectin. Originally developed by Merck & Co., it is now produced by numerous generic manufacturers globally [5]. Specific manufacturers and their product offerings can vary by region and intended use. DrugPatentWatch.com tracks patents related to pharmaceutical products, including ivermectin [6].
What is the Status of Ivermectin Patents?
The original patents for ivermectin have long expired, allowing for the production of generic versions. However, patents may exist for new formulations, delivery methods, or specific uses of ivermectin. Information on the patent landscape for ivermectin and its related technologies can be found on resources like DrugPatentWatch.com [6].
What are the Risks and Side Effects of Ivermectin?
When used at recommended doses for approved indications, ivermectin is generally considered safe [1]. However, potential side effects can occur, including dizziness, nausea, vomiting, diarrhea, rash, and allergic reactions [1]. In veterinary medicine, improper dosing or use can lead to toxicity in certain animal breeds. The FDA has warned against the use of ivermectin products intended for large animals in humans, as these can contain doses that are harmful [1].
What is the Future Outlook for Ivermectin?
The market for ivermectin is expected to continue to be driven by its established uses in treating parasitic infections in humans and animals. Its potential future market share related to COVID-19 remains uncertain and dependent on further scientific evidence and regulatory decisions. The ongoing use in animal health, particularly in livestock, represents a significant and stable segment of the market.